Gilead Exercises Option for MacroGenics Bispecific Program, Triggering $10M Milestone
GILD sits 25% above its 52-week low of $108.46.
Summary
Gilead exercised its option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million milestone payment. MacroGenics remains eligible for up to approximately $1.6 billion in additional development milestones. This follows Gilead's recent $3.15 billion Tubulis acquisition and multiple regulatory wins, reinforcing its aggressive expansion in oncology and virology. For Gilead, the deal adds a new preclinical asset to its pipeline; for MacroGenics, the milestone provides non-dilutive capital and validates its platform. The program's early stage means material revenue impact is years away, but the option exercise signals Gilead's confidence in the target.
At the time of this announcement, GILD was trading at $135.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $168.3B. The 52-week trading range was $108.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.